Key Highlights

  • Shares fell 1.36% to USD 27.58 on relative Volume of 3.02.
  • The Phase 2 atopic dermatitis study missed its primary itch endpoint.
  • Third-quarter net loss was USD 75.6 million, against USD 67.0 million.
  • Cash and marketable securities were USD 650.3 million at September 30.

Celldex (NASDAQ:CLDX) shares traded at USD 27.58 on November 20, 2026, down 1.36%, with a relative volume at time of 3.02. The company has given no reason for the heavy trading. Separately, it announced after the close on November 19 that its Phase 2 atopic dermatitis study of barzolvolimab missed its primary itch endpoint, and it filed its report for the quarter ended September 30, 2026 on November 5.

Celldex is a Delaware corporation based in Hampton, New Jersey. It develops antibody-based therapeutics for inflammatory and other hard-to-treat diseases, led by barzolvolimab, an antibody aimed at the KIT receptor on mast cells. It operates as one segment, reports recurring losses and had total revenues of USD 0.04 million for the nine months ended September 30. Its fiscal year ends on December 31.

The Atopic Dermatitis Study

The Phase 2 study in moderate-to-severe atopic dermatitis missed its primary itch endpoint and the key secondary endpoints, EASI and IGA. At the 300 mg dose, the result was negative 29.2% versus negative 19.5% for placebo (p=0.187). The company is discontinuing barzolvolimab development in that indication. It also said a Biologics License Application for chronic spontaneous urticaria is planned for 2027, Phase 3 studies in cold urticaria and dermographism are enrolling, and new indications will be announced by year end.

The Third Quarter

There were no revenues in either period. Research and Development expense was USD 67.4 million versus USD 62.9 million, and general and administrative expense was USD 14.8 million versus USD 10.7 million. The operating loss was USD 82.3 million versus USD 73.6 million. The net loss was USD 75.6 million, or USD 0.96 per share, against USD 67.0 million, or USD 1.01.

Over nine months, revenues were USD 0.04 million versus USD 1.4 million. Research and development expense was USD 208.0 million versus USD 169.7 million, and general and administrative expense was USD 39.4 million versus USD 31.9 million. The operating loss was USD 247.3 million versus USD 200.2 million, and the net loss was USD 227.7 million, or USD 3.06 per share, versus USD 177.4 million, or USD 2.67.

Cash and Capital

Cash and cash equivalents were USD 27.0 million and marketable securities were USD 623.4 million. Total Assets were USD 721.5 million versus USD 583.0 million at December 31, 2025, and total liabilities were USD 72.1 million versus USD 55.8 million. Operating Activities used USD 188.0 million versus USD 147.0 million.

In April 2026 the company sold 11,896,750 shares in an underwritten offering for net proceeds of USD 323.8 million. Its at-the-market agreement expired on November 3 with no shares sold. The company believes its cash, equivalents and marketable securities will fund planned operations for at least the next twelve months and may take further steps to raise capital.

The Chronic Urticaria Program

In September, Celldex announced topline results from two Phase 3 studies of barzolvolimab in chronic spontaneous urticaria. It said they met the primary and all key secondary endpoints at Week 12 across both studies and both dose groups. Treatment continues in both trials to 52 weeks, and a Biologics License Application is anticipated in 2027.

What to Watch Next for Celldex

The company has given no reason for the November 20 trading. The study announcement and the Quarterly Report are separate, dated events. The reported record shows a wider quarterly loss and a cash position that management calls sufficient for twelve months. The 2027 filing plan and the new indications due by year end are the points to follow.